Riga, undefined

Gersh I Kleiner


Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 1984

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **The Innovations of Gersh I Kleiner**

Introduction

Gersh I Kleiner, an esteemed inventor based in Riga, SU, has made significant contributions to the field of biomedicine. He is best known for his innovative work related to fibrinolysis, particularly through the development of a unique polysaccharide derivative. With a focus on enhancing medical treatments, his inventions are paving the way for advanced therapeutic options.

Latest Patents

Kleiner holds a pivotal patent titled "Dextran derivative of fibrinolysin." This patent details a method for preparing a polysaccharide derivative of fibrinolysin by reacting fibrinolysin with dextran dialdehyde, achieving a specialized covalent bond under specific pH and temperature conditions. This process is crucial for the formation of fibrinolysin derivatives that can be further reduced and isolated using sodium borohydride, highlighting its potential applications in medical therapies.

Career Highlights

Kleiner is affiliated with the All-Union Cardiological Scientific Center, where he has collaborated on several groundbreaking projects. His work has not only contributed to the understanding of cardiovascular health but also provided a framework for future innovations in medical science.

Collaborations

Throughout his career, Gersh I Kleiner has had the opportunity to work alongside notable professionals such as Evgeny I Chazov and Vladimir N Smirnov. These collaborations highlight the importance of teamwork in advancing research and developing innovative medical solutions.

Conclusion

Gersh I Kleiner's inventions and patents represent significant advancements in the medical field, particularly in the area of fibrinolysis. His dedication to research and collaboration continues to inspire future innovations, making a lasting impact on healthcare and patient treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…